Your neighbor’s teenager has Friedreich ataxia. The neurology team talks about heart checks, balance work, and supervised exercise. That night a wellness influencer posts that an “NAD booster” plus workouts “fixed fitness” in a big ataxia trial. The parent forwards the clip and asks whether a catalog vial belongs next to the exercise plan.
There is a careful randomized study. Nicotinamide riboside alone did not clearly beat control. Exercise mattered. A research powder is not that trial.
What the Philadelphia factorial trial measured
Lin and colleagues reported a twelve-week, single-center, 2-by-2 factorial randomized trial in The Lancet Neurology in 2026. Sixty-six children and adults with Friedreich ataxia who could exercise were assigned to nicotinamide riboside alone, exercise alone, both, or neither (with attention-control phone calls). Exercise plans were individualized at home with remote check-ins. The main outcome was change in peak oxygen use during a supervised exercise test.
Compared with control, the combination of nicotinamide riboside plus exercise improved peak fitness by a statistically significant margin. Nicotinamide riboside without exercise did not. Exercise with placebo sat in between and did not clear the trial’s adjusted significance bar on its own in the primary comparison. Combination therapy was not clearly better than exercise alone. Side effects were mild or moderate and included stomach symptoms, falls, colds, and rashes.
In plain terms: adding a supervised exercise program was the part that moved the fitness needle. The NAD precursor by itself did not earn a win.
How this sits next to other NAD+ stories
Prior Everyday Brief NAD pieces looked at blood-marker boosts without anti-aging proof, IV drip visits that mainly logged tolerability, the large Parkinson NOPARK miss, and a mild cognitive impairment pilot where cognition stayed flat. Friedreich ataxia is a separate rare-disease question with its own cardiopulmonary endpoint. Raising NAD is not a substitute for specialty care.
MedlinePlus describes Friedreich ataxia as a genetic condition that needs coordinated neurology and heart monitoring. That path does not run through a research-catalog shelf.
What to ask the ataxia team
Ask what exercise plan is safe for this person’s heart and balance, who will supervise it, and how fitness will be measured. If an NAD booster comes up, ask whether the influencer means this Lancet Neurology factorial trial, and note that nicotinamide riboside alone did not separate from control on the primary fitness outcome.
A rigorous rare-disease trial can still be misread as a shopping tip. For Friedreich ataxia, the clearest signal here favored structured exercise, not a solo booster.
Not medical advice.
Sources
- Lin KY et al. Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich’s ataxia. Lancet Neurol, 2026 (PubMed)
- Full text: Lin et al. 2026 Friedreich ataxia NR and exercise trial (PubMed Central)
- ClinicalTrials.gov: NCT04192136
- MedlinePlus: Friedreich ataxia
Related reading
- NOPARK phase 3: no disease-modifying win in Parkinson disease
- Mild cognitive impairment pilot: thinking scores stayed flat
- Higher blood NAD markers are not anti-aging proof
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-15 PT. Not medical advice.